Forms of mineralocorticoid hypertension

被引:12
作者
Ferrari, P [1 ]
Bonny, O [1 ]
机构
[1] Univ Bern, Div Nephrol & Hypertens, Inselspital, CH-3010 Bern, Switzerland
来源
VITAMINS AND HORMONES - ADVANCES IN RESEARCH AND APPLICATIONS, VOL 66 | 2003年 / 66卷
关键词
D O I
10.1016/S0083-6729(03)01004-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hypertension with hypokalemia, metabolic alkalosis, and suppressed plasma renin activity defines mineralocorticoid hypertension. Mineralocorticoid hypertension is the consequence of an overactivity of the epithelial sodium channel expressed at the apical membrane of renal cells in the distal nephron. This is usually the case when the mineralocorticoid receptor is activated by its physiologic substrate aldosterone. The best known form of mineralocorticoid hypertension is an aldosterone-producing adrenal tumor leading to primary aldosteronism. Primary aldosteronism can also be caused by unilateral or bilateral adrenal hyperplasia and rarely adrenal carcinoma. Interestingly, most of the inherited monogenic disorders associated with hypertension involve an excessive activation of the mineralocorticoid axis. In some of these disorders, mineralocorticoid hypertension results from activation of the mineralocorticoid receptor by other steroids (cortisol, deoxycorticosterone), by primary activation of the receptor itself, or by constitutive overactivity of the renal epithelial sodium channel. The present review addresses the physiology and significance of the key players of the mineralocorticoid axis, placing emphasis on the conditions leading to mineralocorticoid hypertension. © 2003 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:113 / 156
页数:44
相关论文
共 232 条
  • [121] LIDDLE GW, 1963, T ASSOC AM PHYSICIAN, V76, P199
  • [122] HEREDITARY HYPERTENSION CAUSED BY CHIMERIC GENE DUPLICATIONS AND ECTOPIC EXPRESSION OF ALDOSTERONE SYNTHASE
    LIFTON, RP
    DLUHY, RG
    POWERS, M
    RICH, GM
    GUTKIN, M
    FALLO, F
    GILL, JR
    FELD, L
    GANGULY, A
    LAIDLAW, JC
    MURNAGHAN, DJ
    KAUFMAN, C
    STOCKIGT, JR
    ULICK, S
    LALOUEL, JM
    [J]. NATURE GENETICS, 1992, 2 (01) : 66 - 74
  • [123] A CHIMERIC 11-BETA-HYDROXYLASE ALDOSTERONE SYNTHASE GENE CAUSES GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM AND HUMAN HYPERTENSION
    LIFTON, RP
    DLUHY, RG
    POWERS, M
    RICH, GM
    COOK, S
    ULICK, S
    LALOUEL, JM
    [J]. NATURE, 1992, 355 (6357) : 262 - 265
  • [124] High prevalence of primary aldosteronism in the Tayside hypertension clinic population
    Lim, PO
    Dow, E
    Brennan, G
    Jung, RT
    MacDonald, TM
    [J]. JOURNAL OF HUMAN HYPERTENSION, 2000, 14 (05) : 311 - 315
  • [125] Potentially high prevalence of primary aldosteronism in a primary-care population
    Lim, PO
    Rodgers, P
    Cardale, K
    Watson, AD
    MacDonald, TM
    [J]. LANCET, 1999, 353 (9146) : 40 - 40
  • [126] The neurohormonal natural history of essential hypertension: towards primary or tertiary aldosteronism?
    Lim, PO
    Struthers, AD
    MacDonald, TM
    [J]. JOURNAL OF HYPERTENSION, 2002, 20 (01) : 11 - 15
  • [127] A review of the medical treatment of primary aldosteronism
    Lim, PO
    Young, WF
    MacDonald, TM
    [J]. JOURNAL OF HYPERTENSION, 2001, 19 (03) : 353 - 361
  • [128] Lim PO, 1999, BRIT J CLIN PHARMACO, V48, P756
  • [129] PLASMA ALDOSTERONE-PLASMA RENIN-ACTIVITY RATIO - A SIMPLE TEST TO IDENTIFY PATIENTS WITH PRIMARY ALDOSTERONISM
    LINS, PE
    ADAMSON, U
    [J]. ACTA ENDOCRINOLOGICA, 1986, 113 (04): : 564 - 569
  • [130] Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism
    Litchfield, WR
    New, MI
    Coolidge, C
    Lifton, RP
    Dluhy, RG
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (11) : 3570 - 3573